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E-mail address: miki.mgen@mri.tmd.ac.jp (Y. MikiThe chicken DT40 cell line is widely used for gene knock-outs. We attempted to introduce a
polymerase-dead point mutation into Polj, a polymerase for translesion DNA synthesis, taking
advantage of the highly efﬁcient targeted integration in DT40 cells. The resulting cells
(REV3/POLK/pol-dead) proliferated with the same kinetics as the parental REV3/ cells. Though
the mock-treated REV3/POLK/mock cells showed the same sensitivity as the parental REV3/ cells
to methyl methanesulfonate, the REV3/POLK/pol-dead cells demonstrated the same sensitivity as
the REV3/POLK/ double knock-out cells. This implies that the presence of the polymerase-dead
Polj does not interfere with other polymerases repairing monoalkylation damage.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The chicken B-lymphocyte line DT40 is characterized by a high
efﬁciency of genome targeted integration and has been widely
used as a unique tool for gene knock-outs [1]. This suggests that
not only gene knock-outs but also introduction of point mutations
can be done efﬁciently with this cell line [2]. The introduction of
point mutations provides additional information to gene knock-
out experiments, since they generate a gene product retaining
other potentially functional regions of the molecules inside cells.
We attempted to introduce a point mutation into the POLK
gene, which encodes a DNA polymerase specialized for translesion
DNA synthesis (TLS) [3,4]. The POLK gene was chosen for several
reasons. First, DT40 cells possess only a single POLK gene in the
sex chromosome [5], so that a single recombination step into one
allele is sufﬁcient for replacement of wild-type with mutant pro-
tein. Second, Polj has a conserved amino acid that is essential
for its activity [3]. This enables us to downregulate its activity by
a single point mutation, presumably without affecting other func-
tional molecular regions. Third, phenotypes of POLK knock-out
cells have been revealed previously, so that we can compare the
knock-out cells with the cells carrying a point mutation. We have
reported that in the REV3/ background, knock-out of the POLK
gene (REV3/POLK/) resulted in increased sensitivity to mono-chemical Societies. Published by E
).functional alkylating agents including methyl methanesulfonate
(MMS) [6]. We can therefore use MMS sensitivity as a reference
for analysis in the REV3/ background.
In this paper, we designed a knock-in construct for the intro-
duction of a polymerase-dead point mutation into the chicken
POLK gene. We successfully substituted an aspartate residue in
the active site to inactivate the Polj activity without affecting its
expression. The resulting REV3/POLK/pol-dead cells exhibited the
same sensitivity as the REV3/POLK/ cells, which is signiﬁcantly
higher than that of the parental REV3/cells.
2. Materials and methods
2.1. Construction of the knock-in vector
The knock-in construct to introduce a catalytic-null point muta-
tion into POLK, and a construct for mock treatment were generated
from genetic PCR products combined with puromycin-selection
marker cassette. Genomic DNA sequences for 50-arm of 1.3 kb were
ampliﬁed using the primers 50-CGGTACCTCAGACTTCATCAATG
CATCAGTTTTAG-30 and 50-CATCGATAGGCTTTTGTGCATGGGTGAG-
TAGTAGA-30 with the KOD-Plus-DNA polymerase (Toyobo). To
introduce the point mutation, this fragment was subjected to
site-directed mutagenesis by PCR using the primers 50-GCCTAT-
GGGCCTAAATGAAGCCTACCTGAATG-30 and its complementary oli-
gonucleotides with Pfx50 DNA polymerase (Invitrogen). Genomic
DNA sequences for the 4.5 kb 30-arm were ampliﬁed using thelsevier B.V. All rights reserved.
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and 50-CGAGCTCAGCACAAGAGTAGCCTACACTTGTGGT-30. The
KpnI–ClaI fragment of 50-arm and the NotI–SacI fragment of 30-
arm were sequencially subcloned into pLoxPuro vector, a pBlue-
scriptII KS(+) carrying the puromycin-resistance marker ﬂanked
by two different mutant loxP sites [7]. All the PCR-ampliﬁed frag-
ments were sequenced to conﬁrm that they did not contain any
PCR errors.
2.2. Cell culture and gene-targeted knock-in
DT40 cells were cultured in RPMI1640 supplemented with
0.5 mM 2-mercaptoethanol, 10% fetal calf serum and 1% chicken
serum at 37 C in a 5% CO2 atmosphere. The knock-in vectors were
cut with KpnI and transfected to the cells as described [8]. Drug-
resistant colonies were selected with medium containing 0.5 lg/ml
puromycin, and subjected to genome DNA extraction. Targeting
events were veriﬁed by the presence of the 1.4 kb-genomic PCR6 7 8
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Total RNA was extracted using the RNeasy Mini Kit (Qiagen).
RT-PCR with the primers P1, 50-CATTCAGGTAGGCTTCATTTA
GGCCCATAGGC-30 (P2), 50-GCCTATGGGCCTAAATGAAGCCTACCT-
GAATG-30 (P5), 50-TCACAGCTTCTTCTGCAGAGGTTCCAAAGACA-30
(P6), 50-GGCACATCTGTAATGGATGATGACTCTGGACA-30 (P7) and
50-ATGAAGTCTAGCACTGCTTGTCTCTCTGGAGA-30 (P8) was performed
using SuperScript III One-Step RT-PCR System with Platinum Taq
DNA polymerase (Invitrogen) according to the manufacturer’s
instruction.
2.4. Colony formation assay
Colony formation assay of DT40 cells with media containing
methylcellulose was performed for measuring sensitivities to
methyl methanesulfonate (MMS) as previously described [5].
3. Results and discussion
3.1. Production of the cells that have a polymerase-dead POLK gene
We have attempted to introduce a polymerase-dead point
mutation into the active site of POLK. The aspartic acid (Asp) at
the active site is conserved in POLK family members (Fig. 1A) [3].
Since this Asp is located in exon 7, we positioned the puromycin-
resistance selection marker, ﬂanked by two different mutant loxP
sites, at the beginning of intron 7 (Fig. 1B).
The short 50-arm and the long 30-arm were designed to be more
than 5 kb in total and ampliﬁed by PCR. The fragments, which were
free of PCR errors, were ligated into the vector carrying the puro-
mycin marker to make the knock-in constructs. We prepared two
constructs: one was without any mutation for mock treatment,A RT-PCR P1—P2
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Fig. 2. Analyses of the POLK expression by RT-PCR in mutated cells. (A) RT-PCR
using the primers P1 and P2 (exons 6 and 7). The same amounts of RNA extracted
from the each cell line were used. (B) RT-PCR using the primers P5 and P6 (exons 7
and 8). (C) RT-PCR using the primers P7 and P8 (exons 8 and 9). (D) RT-PCR using
the primers P5 and P8 (exons 7 and 9).and the other was subjected to site-directed mutagenesis for the
introduction of a point mutation of an amino acid change from
the Asp to Asn.
Each construct was transfected into REV3/ cells and the tar-
geted colonies were selected. The efﬁciency for knock-in was high
and the same as the knock-out efﬁciency in DT40 cells; one tar-
geted clone was derived from 15 to 50 drug-resistant clones. The
resulting cells, REV3/POLK/pol-dead(puro) and REV3/POLK/mock(puro)
cells, were respectively transfected with a Cre expression plasmid
transiently, and REV3/POLK/pol-dead and REV3/POLK/mock cells
were generated. By genomic sequencing, as expected, a fragment
of 82 bp consisting of mutant loxP sites and a part of the knock-
in construct was left in the intron with or without the change from
Asp to Asn in the POLK locus (Fig. 1C).
For veriﬁcation of the production of the cells we performed
genomic PCR.With primers P1 and P2 (Fig. 1A), PCR fragments were
ampliﬁed except for the REV3/POLK/ cells (Fig. 1E), in which the0.1
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Fig. 3. Analyses of the REV3/POLK/pol-dead cells. (A) Growth kinetics of the
REV3/POLK/, the REV3/POLK/mock and the REV3/POLK/pol-dead cell lines. (B–E)
Higher MMS sensitivity of the REV3/POLK/pol-dead cells than that of the
REV3/POLK/mock cells. (B) Higher MMS sensitivity of the multiple clones for the
REV3/POLK/mock(puro) cells than that for the REV3/POLK/mock cells. (C) Higher MMS
sensitivity of the multiple clones for the REV3/POLK/pol-dead cells. (D) The MMS
sensitivity of the all cell lines comparing with that of the REV3/ and the
REV3/POLK/ cells. (E) The same as in D in different scale. The indicated genotypes
were exposed to MMS for 1 h in RPMI1640 media without serum. The concentra-
tions of MMS are displayed on the x axis on a linear scale, while the fractions of
surviving colonies are displayed on the y axis on a logarithmic scale. Error bars
show the S.E. for at least three independent experiments. WT, wild-type.
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the primers P3 and P4 failed with the REV3/POLK/mock(puro)
genome, because of the presence of the puromycinmarker between
the primers (Fig. 1F, lane 4). In contrast, ampliﬁcation with the
REV3/POLK/mock and the REV3/POLK/pol-dead genomes conﬁrmed
the absence of the marker (Fig. 1F, lanes 5 and 6).
Furthermore, we sequenced around the catalytic center of the
REV3/POLK/mock and the REV3/POLK/pol-dead cells and veriﬁed
that in the former cells the Asp was not changed (Fig. 1G), but it
was changed to the Asn in the latter cells (Fig. 1H).
The expression of POLK was tested by RT-PCR with the primers
P1 and P2. Like in the parental REV3/ cells (Fig. 2A–D, lane 2),
mRNA was expressed both in the REV3/POLK/mock and the
REV3/POLK/pol-dead cells (Fig. 2A–D, lanes 5 and 6). This suggested
that the procedures for the production of these cells did not affect
the expression of the gene.
3.2. Phenotypic analysis of the REV3/POLK/pol-dead cells
Phenotypic analysis was carried out for the knock-in cells
comparing them with the parental REV3/ and the knock-out
REV3/POLK/ cells. First, we asked if the genome manipulations
affected the growth rate of the knock-in cells. The growth rate of
the REV3/POLK/mock and the REV3/POLK/pol-dead cells was indis-
tinguishable from that of REV3/POLK/ cells (Fig. 3A), which
proliferates with the same kinetics as the parental REV3/ cells
[6]. The intermediate REV3/POLK/mock(puro) cells exhibited the
same growth rate (data not shown). Second, the sensitivity to
MMS was measured using independently generated multiple clones
for each cell line. We had already reported that the REV3/POLK/
double knock-out cells exhibited higher sensitivity than the
REV3/ single knock-out cells to monofunctional alkylating agents
including MMS [6]. The intermediate REV3/POLK/mock(puro) cells
exhibited the same sensitivity as the REV3/POLK/ cells (Fig. 3B
and D). This suggested that the presence of the puromycin marker
in the intron may have knocked out the Polj product presumably
by inhibiting the correct mRNA splicing. This idea is consistent
with the results of RT-PCR, where the correctly spliced mRNA for
POLK was missing (Fig. 2B–D, lane 4). In contrast, after removing
the puromycin marker from those cells, the REV3/POLK/mock cells
had the same sensitivity as the parental REV3/ cells (Fig. 3B and
D). This suggested that the short sequences derived from the
knock-in construct left in the intron (82 bp in this instance) did
not block the expression of POLK, consistent with the results of
RT-PCR (Fig. 2A–D, lane 5). The sensitivity of the REV3/POLK/pol-dead
cells was examined and resulted in the same sensitivity as the
knock-out REV3
/POLK/ cells (Fig. 3C and D). This suggested that
the polymerase-dead point mutation of POLK showed the same
phenotype as the gene knock-out. In fact we had hypothesized that
the polymerase-dead Polj might be recruited to the damaged site
normally but get stuck since it could not process the DNA polymer-
ization. Had that been the case, the sensitivity to MMS might havebeen more severe than the simple knock-outs of the gene. Our
present results suggest that it is not the case for Polj. The catalyt-
ically inactive Polj would be removed from the damaged sites and
another responsible polymerase would be recruited efﬁciently.
In conclusion, we have succeeded in introducing a point
mutation into the POLK gene in DT40 cells. The resulting
REV3/POLK/pol-dead cells had the same sensitivity as the gene
knock-out REV3/POLK/ cells. An important step for function of
Polj is the recruitment to damaged sites, probably protein inter-
acting sequences in the C-terminal [10–12]. Introducing mutations
into those sites would help to uncover the molecular mechanism
for recruiting Polj to damaged sites in future.
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